Cohance Lifesciences Limited
COHANCE
Rangering i aksjer
#6337
Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a... Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.
Aksjekurs
$5.09
Markedsverdi
$1.95B
Endring (1 dag)
0.79%
Endring (1 år)
-57.04%
Land
IN
Handel Cohance Lifesciences Limited (COHANCE)
Kategori
Healthcare
P/B-forhold for Cohance Lifesciences Limited (COHANCE)
P/B-forhold per October 2026 TTM: 22.54
Ifølge Cohance Lifesciences Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 22.54. Ved slutten av 2024 hadde selskapet et P/B-forhold på 8.31.
P/B-historikk for Cohance Lifesciences Limited fra 2019 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 22.54 | 41.50% |
| 2025 | 15.93 | 91.72% |
| 2024 | 8.31 | 19.91% |
| 2023 | 6.93 | -32.77% |
| 2022 | 10.31 | -3.75% |
| 2021 | 10.71 | 253.56% |
| 2020 | 3.03 | -58.32% |
| 2019 | 7.27 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -77.64% |
IN
|
